AIM ImmunoTech Inc Dossier
Qualitative Analysis
Business overview
AIM ImmunoTech Inc. is an immuno-pharmaceutical company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders. The company's flagship product is Ampligen (rintatolimod), a double-stranded RNA (dsRNA) macromolecule and highly selective TLR3 agonist immuno-modulator. Ampligen is being actively evaluated in clinical trials for late-stage pancreatic cancer, recurrent ovarian cancer, and post-COVID fatigue (Long COVID). Additionally, the company owns Alferon N Injection, an injectable formulation of natural source alpha interferon approved in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Concentrating research and development efforts on advancing the lead drug candidate, Ampligen (rintatolimod), for the treatment of late-stage pancreatic cancer, specifically through the Phase 2 DURIPANC study in combination with AstraZeneca's Imfinzi.
Expected impact: Aims to utilize exploratory biomarker data to design a targeted Phase 3 study, positioning the company for potential acquisition or licensing by a larger pharmaceutical entity.
Strengthening the company's balance sheet and financial flexibility by raising capital through equity-generating transactions (such as warrant inducements, rights offerings, and at-the-market offerings) and extending debt maturities.
Expected impact: Successfully resolved the stockholder equity deficiency to regain NYSE American compliance, increasing stockholder equity by $11.9 million in Q1 2026 and enhancing capital allocation flexibility.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Collaborating on the Phase 2 DURIPANC clinical trial evaluating Ampligen in combination with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) for metastatic pancreatic cancer.
Terms: The trial is funded in part by AstraZeneca, helping to reduce clinical development costs for AIM ImmunoTech.
Collaborating on a Phase 2 clinical trial evaluating Ampligen in combination with checkpoint inhibition (pembrolizumab) and chemotherapy in recurrent ovarian cancer.
Terms: Collaborative clinical trial framework with shared development interest; specific financial terms are not publicly disclosed.
Serving as the exclusive sales agent for AIM's at-the-market (ATM) public offering program and acting as dealer-manager for its rights offerings.
Terms: Amended on April 10, 2026, to remove the previous $3,000,000 cap on the amount of common stock that can be sold, allowing for expanded capital raising under the shelf registration statement.